ClinicalTrials.gg
Not yet recruitingNCT07683026Updated Jul 6, 2026

Platform Trial in Stage 1 Diabetes: Comparing Golimumab vs Placebo

A Phase 2 interventional study of Golimumab and Placebo (matching golimumab) in Type 1 Diabetes (T1D), sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Not yet recruiting at 1 site in United States. Open to participants aged 2 Years to 44 Years. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Phase 2, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
255
Allocation
Randomized
Ages
2 Years to 44 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 42 studies in Diabetes Mellitus, Type 1 by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) — 3 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus, Type 1 · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

Planned enrollment
5th of 32
255 · median 83
Started
2026
with 2 others
Phase 2
22 of 42
3 open now
Registered
42nd of 42
by date

Among the 42 studies in Diabetes Mellitus, Type 1 by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), this one is the 5th largest by planned enrollment of the 32 interventional ones that give a count, is one of 3 that started in 2026, is one of 22 in phase 2, and was the 42nd registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

3 of the 42 studies in Diabetes Mellitus, Type 1 by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 2 Years to 44 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Diabetes Mellitus, Type 1 by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if golimumab is effective at preventing progression to Stage 2 diabetes in participants with presymptomatic Type 1 Diabetes. The expected duration of this study is approximately 6 years.

Participants will:

  • Take golimumab or placebo injections monthly for the duration of the study or until they are diagnosed with either stage 2 or stage 3 Type 1 Diabetes
  • Visit a study clinic every 6 months for Oral Glucose Tolerance Tests (OGTTs) and other tests until the end of the study
Read the detailed description

This is a double-masked, multicenter, randomized, placebo-controlled trial to determine whether treatment of participants with presymptomatic T1D (two or more diabetes autoantibodies or IA2 alone) and normal glycemia with golimumab results in delay or prevention of progression to confirmed dysglycemia or symptomatic diabetes. 225 participants with presymptomatic T1D will be randomly assigned to placebo or golimumab at a 1:2 randomization (75 placebo and 150 study drug). Golimumab or a saline placebo will be given as a subcutaneous injection. A loading dose regimen at 0 and 2 weeks will be followed by monthly doses for the duration of the participant's enrollment in the study. Study visits will occur every 6 months with some additional remote monitoring in between visits. Study visit procedures include OGTTs, physical exams, questionnaires, and other laboratory tests. The primary outcome is to determine if intervention with golimumab will prevent or delay the progression to confirmed dysglycemia or overt diabetes in persons less than 18 years of age with presymptomatic T1D. The study is expected to recruit for 3 years followed by an additional 3 years of follow-up for the last participant enrolled.

03

Conditions studied

  • Type 1 Diabetes (T1D)

Keywords

  • TrialNet
  • T1D
  • Golimumab
04

Who can participate

Ages eligible
2 Years to 44 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing to provide or have a parent or legal guardians provide informed consent when the participant is \<18 years of age.
  2. Weight ≥15 kg at the time of screening.
  3. Aged ≥2 to \<45 years.
  4. A confirmed history of either IA2A alone or at least two or more diabetes-related biochemical autoantibodies (mIAA, GADA, ICA, IA-2A, ZnT8A) present on the same sample. Confirmed autoantibody result means that the presence of the antibody has been verified on more than one occasion. For multiple autoantibody positivity, the same autoantibodies do not need to be present on the different tests. Confirmation must occur within the six months prior to screening. In the absence of other antibodies, ICA and GADA positivity alone will not suffice for eligibility in this study.
  5. Oral glucose tolerance test (OGTT) results demonstrating normal glucose tolerance within 7 weeks (52 days) prior to randomization. If a participant has known previous abnormal glucose tolerance, the two most recent OGTTs must demonstrate normal glucose tolerance to be eligible.
  6. CMV and/or EBV seronegative participants must be CMV and EBV PCR negative within 60 days of randomization and may not have had signs or symptoms of a CMV or EBV-compatible illness lasting longer than 7 days within 30 days of randomization.
  7. CMV seropositive participants must be CMV PCR negative and all EBV seropositive participants must have EBV PCR \< 2,000 IU/mL within 60 days of randomization and may not have had signs or symptoms of a CMV or EBV-compatible illness lasting longer than 7 days within 30 days of randomization.
  8. Be at least 4 weeks from last live immunization.
  9. Be willing to forgo during treatment and for 3 months after study drug treatment period.
  10. Must meet TrialNet eligibility minimum immunization recommendations found in Appendix A of the manual of operations (MOO).
  11. Negative Coccidioides serology testing for those who have in the past resided in for at least 2 months, currently reside in, or within the past 2 months have visited an endemic area (as defined in Protocol MOO Appendix B).
  12. If a female participant with , willing to avoid pregnancy (abstinence or adequate method) through up to 3 months after last study drug administration and undergo pregnancy testing at each study visit.

Exclusion criteria

Exclusion Criteria:

  1. One or more screening laboratory values as stated:

    1. Leukocytes \<3,500/μL or >14,000/μL
    2. Neutrophils \<1,500/mL
    3. count \<100,000 /μL
    4. \<6.2 mmol/L (10.0 g/dL)
    5. or ALT ≥ 2 times the (2x ULN)
  2. Abnormal Glucose Tolerance or Diabetes

    1. Fasting plasma glucose ≥100 mg/dL (6.1 mmol/L), or
    2. 2 hour plasma glucose ≥140 mg/dL (7.8 mmol/L), or
    3. 30, 60, or 90 minute plasma glucose during OGTT ≥200 mg/dL (11.1 mmol/L)
  3. History of treatment with insulin except transient use during acute illness or hospitalization.
  4. Vaccination with a within the last 4 weeks or killed/inactivated vaccine within the last 2 weeks prior to randomization.
  5. A history of confirmed infectious mononucleosis within the 3 months prior to randomization, as documented by EBV serology (EBV VCA-IgM and VCA-IgG; PCR would be confirmatory).
  6. Evidence of prior or current tuberculosis (TB) infection through any one or more of the following:

    1. A history of latent or active TB
    2. Signs and/or symptoms of TB
    3. Recent close contact with a person with known or suspected active TB unless appropriate prophylaxis for TB was given
    4. A history of a chest X-ray consistent with active TB or old, inactive TB
    5. A history of a positive purified protein derivative (PPD) skin test result (>10 mm induration), or positive/repeatedly indeterminate on an interferon-gamma release assay (IGRA; e.g., QuantiFERON-TB test).
  7. Prone to infections or has chronic, recurrent or opportunistic infectious disease, including but not limited to Pneumocystis carinii, aspergillosis, latent or active granulomatous infection, or an open, draining, or infected non-healing skin wound or ulcer.
  8. Known active infection or active signs or symptoms of acute or chronic infection at the time of randomization including SARS-Cov-2.
  9. Have or had a demyelinating disorder such as multiple sclerosis or Guillain-Barré syndrome.
  10. Current diagnosis of other diseases except stable and/or adequately treated hypothyroidism and/or celiac disease (participants must be well controlled for the previous 6 months).
  11. Current or ongoing use of non-insulin pharmaceuticals that affect glycemic control within 14 days of the screening visit.
  12. Has previously participated in a clinical trial for diabetes prevention and received active study agent within 6 months of treatment.
  13. History of blastomycosis, histoplasmosis, or coccidioidomycosis.
  14. A history of other than fully treated basal cell or squamous cell carcinoma of the skin.
  15. Have or had moderate to severe congestive heart failure.
  16. Ongoing or anticipated future use of any medications known to impact T1D progression.
  17. Evidence of current or past or or current infection.
  18. Be pregnant or lactating or anticipate becoming pregnant during the study.
  19. Any condition, prior treatment, or laboratory abnormality that in the investigator's opinion may adversely affect study participation or confound study results.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
255 participants (estimated)

Study arms

  • Experimental
    Golimumab

    Participants assigned to this arm will receive golimumab injections

    Drug: Golimumab

  • Placebo comparator
    Placebo

    Participants assigned to this arm will receive saline (placebo) to match Golimumab injections

    Drug: Placebo (matching golimumab)

Interventions

  • Golimumab will be given as a subcutaneous formulation based on the participant's weight at baseline. A loading dose regimen at 0 and 2 weeks will be followed by monthly maintenance doses for the duration of the participant's enrollment in the study. For those weighing 15kg to less than 40 kg the dosing will be: 100mg (week 0), followed by 50mg monthly thereafter. For those weighing 40kg or more the loading dose will be 200mg (week 0) followed by 100mg thereafter.

    Also known as: Simponi

  • DrugPlacebo (matching golimumab)

    0.9% Sodium Chloride Injection USP ("Normal" saline) is to be dispensed as the placebo for this study. A loading dose regimen at 0 and 2 weeks will be followed by monthly maintenance doses for the duration of the participant's enrollment in the study.

    Also known as: Saline

06

What researchers measure

Primary outcomes

  1. Progression to Dysglycemia

    The primary outcome is the elapsed time from random treatment assignment to the development of confirmed dysglycemia or overt hyperglycemia/symptomatic based upon ADA criteria.

    Time frame: From randomization to confirmed dysglycemia or clinical diagnosis of T1D, approximately 6 years from the first participant enrolled.

Secondary outcomes

  1. Progression to overt hyperglycemia/symptomatic Type 1 Diabetes

    Elapsed time from study drug administration to the development of diabetes or time of last contact among those randomized

    Time frame: From Randomization to clinical diagnosis approximately 6 years from the first participant enrolled.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Data will be available at the NIDDK Central Repository

Supporting information: Study protocol, Informed consent form

Time frame: Final datasets will be available at the NIDDK Central Repository 12 months from the last participant's follow-up visit

Access criteria: IPD can be requested through the NIDDK Central Repository once submitted.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Sep 2032, 72 months later.

Of 83 non-industry phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 76. This study's planned 72 months is above that.

Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2026
First posted
Jul 6, 2026
StartEst.
Aug 8, 2026
Primary completionEst.
Sep 1, 2032
CompletionEst.
Sep 1, 2032
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07683026
Responsible party
Sponsor
First posted
Jul 6, 2026
Start date
Aug 8, 2026 (estimated)
Primary completion
Sep 1, 2032 (estimated)
Completion
Sep 1, 2032 (estimated)
Last update
Jul 6, 2026

Study contacts

Ariana Rojas
Contact
Ariana.Rojas@epi.usf.edu
813-974-6827
Jason Gaglia, MD
study chair · TrialNet

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Golimumab

Start the discussion